Swiss National Bank Sells 12,400 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Swiss National Bank lowered its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 10.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 106,660 shares of the biopharmaceutical company’s stock after selling 12,400 shares during the quarter. Swiss National Bank owned approximately 0.19% of Agios Pharmaceuticals worth $2,450,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,225,097 shares of the biopharmaceutical company’s stock valued at $147,766,000 after purchasing an additional 21,396 shares in the last quarter. State Street Corp raised its stake in shares of Agios Pharmaceuticals by 6.7% during the 2nd quarter. State Street Corp now owns 3,401,219 shares of the biopharmaceutical company’s stock worth $75,405,000 after acquiring an additional 214,706 shares in the last quarter. Armistice Capital LLC raised its stake in shares of Agios Pharmaceuticals by 42.9% during the 4th quarter. Armistice Capital LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock worth $77,220,000 after acquiring an additional 826,000 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Agios Pharmaceuticals by 11.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,653,079 shares of the biopharmaceutical company’s stock worth $46,417,000 after acquiring an additional 174,690 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Agios Pharmaceuticals by 27.2% during the 1st quarter. First Trust Advisors LP now owns 1,613,429 shares of the biopharmaceutical company’s stock worth $46,967,000 after acquiring an additional 344,959 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AGIO. JPMorgan Chase & Co. dropped their target price on shares of Agios Pharmaceuticals from $33.00 to $32.00 and set a “neutral” rating on the stock in a research report on Monday, August 7th. StockNews.com began coverage on shares of Agios Pharmaceuticals in a report on Thursday, August 17th. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $36.00.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $26.96 on Wednesday. The company’s fifty day moving average price is $26.97 and its 200 day moving average price is $25.30. Agios Pharmaceuticals, Inc. has a 1 year low of $21.07 and a 1 year high of $34.76. The company has a market capitalization of $1.50 billion, a PE ratio of -7.24 and a beta of 0.95.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.09. Agios Pharmaceuticals had a negative net margin of 1,042.56% and a negative return on equity of 20.24%. The firm had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.46 million. During the same period in the prior year, the firm posted ($1.68) earnings per share. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.29 EPS for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider James William Burns sold 1,707 shares of the company’s stock in a transaction on Friday, June 30th. The shares were sold at an average price of $28.36, for a total transaction of $48,410.52. Following the completion of the transaction, the insider now directly owns 30,285 shares in the company, valued at $858,882.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Agios Pharmaceuticals news, insider James William Burns sold 1,707 shares of the company’s stock in a transaction on Friday, June 30th. The shares were sold at an average price of $28.36, for a total transaction of $48,410.52. Following the completion of the transaction, the insider now directly owns 30,285 shares in the company, valued at $858,882.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Theodore James Jr. Washburn sold 1,232 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $26.26, for a total transaction of $32,352.32. Following the transaction, the insider now owns 5,659 shares of the company’s stock, valued at $148,605.34. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,016 shares of company stock worth $1,645,859. Company insiders own 4.24% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias.